Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation – Business Wire (press release)
|
Vivet's First Gene Therapy Product, VTX 801 for Wilson's Disease, Receives European and US Orphan Drug Designation
Business Wire (press release) PARIS–(BUSINESS WIRE)–Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet's lead gene therapy product, VTX-801, for the … |
